
Peptide Predicts Cardiac Risk in Women With Unblocked Arteries
METHODOLOGY:
The analysis focused on baseline associations between proCNP concentrations in plasma and clinical data in 1508 women with ANOCA, with exploratory analyses examining correlation patterns between proCNP and 185 cardiovascular plasma markers.
Primary outcomes included all-cause death and a composite endpoint of cardiovascular events. Hazard ratios (HRs) were adjusted for age and creatine concentration, which have been linked to proCNP-derived peptides in plasma.
TAKEAWAY:
A high concentration of proCNP (≥ 53.4 pmol/L) was associated with a diagnosis of hypertension ( P = .001) and diabetes mellitus ( P < .001), postmenopausal status ( P < .001), but not age.
= .001) and diabetes mellitus ( < .001), postmenopausal status ( < .001), but not age. The researchers identified 38 plasma markers significantly associated with proCNP, showing positive correlation with atherosclerotic markers and a negative correlation with pro-inflammatory markers.
Women with high concentrations of proCNP were at increased risk for all-cause mortality (crude HR, 1.73; 95% CI, 1.10-2.73; P = .02) and adjusted HR, 1.57; 95% CI, 0.99-2.49; P = .06).
= .02) and adjusted HR, 1.57; 95% CI, 0.99-2.49; = .06). No significant difference was found in rates of cardiovascular events between groups (crude HR, 1.08; 95% CI, 0.72-1.62; P = .71; and adjusted HR, 1.03; 95% CI, 0.68-1.56; P = .90).
IN PRACTICE:
'The association between high proCNP concentrations and diabetes in women is notable as diabetes is associated with an excess risk of > 40% of fatal ischemic heart disease in women compared with men,' the researchers reported. 'Our findings thus raise the question whether increases in proCNP among elderly women are part of an adaptive vascular response to cardiovascular risk factors after menopause. Taken together, the baseline associations of the present study show high proCNP concentration in women with ANOCA is associated with a cardiovascular risk profile independent of NT-proBNP and low-grade inflammation.'
SOURCE:
This study was led by Peter D. Mark, MD, PhD, of the University of Copenhagen, in Copenhagen, Denmark. It appears online in the July 1 issue of JACC: ADVANCES .
LIMITATIONS:
As only women were examined in this study, it was impossible to evaluate whether the findings would be mirrored in men with ANOCA. Biomarkers, except for proCNP and high-sensitivity C-reactive protein, were quantified as relative plasma levels rather than absolute concentrations, limiting the interpretation of the statistical analyses.
DISCLOSURES:
This study received support through the Danish Biotek program via a grant from the Danish Health Ministry. The senior author, Jens P. Goetze, has served as a consultant for Novo Nordisk on biochemical method development.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and scalability. Its model integrates telehealth consultations, electronic medical records, cloud-based pharmacy fulfillment and artificial intelligence (AI)-driven care routing — creating a seamless end-to-end user experience across conditions like mental health, dermatology, sexual wellness and weight management. HIMS' subscription-based approach reached 2.4 million subscribers in first-quarter 2025, with over 1.4 million using personalized solutions, reflecting strong demand for tech-enabled care. Central to Hims & Hers' strategy is its expanding investment in AI. The recent appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal move toward scaling intelligent, individualized care. Elshenawy brings over two decades of experience in AI, robotics and cloud infrastructure, and is tasked with enhancing diagnostics, automation and platform personalization. These efforts are supported by an $870 million upsized convertible notes offering, with proceeds earmarked for AI innovation and global expansion. Hims & Hers is also vertically integrating its operations through acquisitions in pharmacy and diagnostics, enabling greater control over fulfillment and care quality. Tools like MedMatch use data to route patients to the right care pathways, while new AI applications aim to automate and refine diagnosis and treatment recommendations. By blending direct-to-consumer infrastructure with advanced technology, Hims & Hers is enhancing healthcare delivery for millions — offering a scalable model that delivers high-quality, personalized care with efficiency. LFMD & DOCS' Digital-First Transformation LifeMD, Inc. LFMD has rapidly evolved into a comprehensive digital-first healthcare platform offering vertically integrated telehealth solutions. With LifeMD's nationwide physician network, proprietary electronic medical records and in-house pharmacy operations, it delivers personalized care at scale. LFMD supports recurring subscription models across multiple specialties, including weight management and primary care. LifeMD's tech-enabled ecosystem enhances clinical access, operational efficiency and long-term subscriber value through continuous innovation. Doximity, Inc. DOCS continues to redefine physician engagement through its digital-first strategy, offering HIPAA-compliant telehealth tools and AI-powered workflow enhancements. Doximity enables doctors to connect, consult and collaborate seamlessly within its professional network. DOCS' platform integrates secure messaging, eFax and personalized newsfeeds, reflecting Doximity's mission to streamline clinical operations and empower providers with intelligent, scalable solutions. HIMS' Price Performance, Valuation and Estimates Shares of Hims & Hers have gained 171% year to date, outperforming the industry's growth of 10.7%. Image Source: Zacks Investment Research HIMS' forward 12-month P/S of 5.6X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 177.8% improvement from 2024. Image Source: Zacks Investment Research Hims & Hers stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report LifeMD, Inc. (LFMD) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
31 minutes ago
- Yahoo
Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the stocks under $10 to buy now. On July 17, Eledon Pharmaceuticals announced that updated clinical data from its ongoing open-label Phase 1b study of tegoprubart will be presented at the World Transplant Congress/WTC. The WTC will take place in San Francisco from August 2-6 this year. The oral presentation, titled 'Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,' will feature updated results from ~30 kidney transplant recipients. In addition to the oral presentation, Eledon Pharmaceuticals will sponsor a satellite symposium at the WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?' A scientist in a laboratory holding a vial of medication developed by the biotechnology company. Furthermore, new preclinical data on tegoprubart's use for preventing rejection in non-human primates undergoing liver transplantation will be presented in a poster session. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that uses its immunology expertise in targeting the CD40 Ligand/CD40L pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis/ALS. While we acknowledge the potential of ELDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
33 minutes ago
- Yahoo
Michigan moms could soon have easier access to group prenatal care that's changing lives
Picture this: instead of rushing through a prenatal appointment alone, you join a circle of eight or so expectant parents due around the same time. Over 90 relaxed minutes, you learn about stress management and breastfeeding, get individual check-ins from your provider, and build real relationships with other parents-to-be who actually get what you're going through. This is the heart of CenteringPregnancy, and if new legislation moves forward, moms across Michigan could soon have better access to this kind of support. On July 1, the Michigan Senate passed Senate Bills 414 and 415, which would require both private insurers and Medicaid to cover these group-based prenatal care programs. Related: New CDC data shows that more pregnant women are unable to access prenatal care Why it matters: the science of community prenatal care The idea is simple: you get your prenatal care in a group setting, alongside other pregnant people. But the impact goes way beyond the check-up. CenteringPregnancy helps normalize the experience of motherhood, offering emotional support and measurable health benefits. Studies have shown major benefits: A 33–47% drop in preterm births in randomized trials, with even stronger effects for Black mothers—a meaningful step toward addressing racial disparities in birth outcomes. A 40% reduction in postpartum depression symptoms at six months, according to a meta-analysis. For families already facing barriers to care, these improvements are life-changing. More than medical care: building a village Beyond the metrics, the emotional benefit of group prenatal care is hard to overstate. CenteringPregnancy creates space for parents to share fears, questions, and excitement with people on the same journey. It turns what can feel like a medical transaction into a shared rite of passage. For many moms, it means leaving appointments feeling empowered, informed, and less alone. It can also help detect mental health challenges earlier, improve breastfeeding success, and reduce feelings of isolation that so often accompany pregnancy and postpartum life. What the Michigan bills would change The two bills passed by the Senate aim to make this model a standard part of care—not just a nice-to-have pilot. Senate Bill 414 would require private insurers who already cover prenatal care to include group prenatal care in their plans. Senate Bill 415 would permanently secure Medicaid coverage for CenteringPregnancy in Michigan. (Medicaid already reimburses for it—but this law would ensure it stays that way.) By putting these requirements into law, the state would ensure consistent, widespread access, even if budgets or administrations change. Related: New York is officially the first state to mandate PTO for prenatal care A model the rest of the country should be watching Supporters of the legislation see Michigan as a potential national example. They argue that expanding CenteringPregnancy access is one of the simplest ways to improve maternal and infant health while also saving money on avoidable NICU stays and complications. For families, it represents a shift away from fragmented, rushed care toward a model that's relational, supportive, and proven to work. As a mom of five kids who was underwhelmed with the traditional prenatal care model, I'm excited about a healthcare system that doesn't just provide clinical insights, but also human connection. What's more intimate, life-transforming, and support-group worthy than bringing a new baby into the world? Sources: CenteringPregnancy: A model of group prenatal care. 2023. Centering Healthcare Institute. CenteringPregnancy: A model of group prenatal care. Group prenatal care reduces risk of preterm birth. October 2016. YaleNews. Group prenatal care reduces risk of preterm birth. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. November 2019. Obstetrics & Gynecology. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. SB 414 and SB 415. July 2024. Michigan Legislature. SB 414 and SB 415.